Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Trial details
- Registry ID
- NCT04562389
- Phase
- Phase 3
The FDA approved Selinexor (KPT-330) on 3 Jul 2019.
Drug identity checked against registry records
Also recorded as KPT-330; XPOVIO; XPOVIO®; Xpovio
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2019-07-03Day | Selinexor | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA212306", "applicant_as_listed_by_fda": "KARYOPHARM THERAPS", "brand_names": ["XPOVIO"], "active_ingredients": ["SELINEXOR"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20190703", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |